Shilpa Medicare commissions state-of-the-art ADC GMP manufacturing facility

Key highlights

• Shilpa Biologicals, subsidiary of Shilpa Medicare, commissioned an integrated ADC Drug Substance GMP facility.
• Facility designed to meet US FDA, EMA, and other global regulatory standards, now operational with GMP qualification underway.
• The facility enables end-to-end ADC manufacturing including payload synthesis, linker development, antibody production, conjugation, and purification.

Why it's rated notable: The filing announces the commissioning of an ADC GMP facility by a material subsidiary but states no capex or investment amount, so the level stays at medium.